Clinical Trial

Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS

Completed
View on ClinicalTrials.gov →
Summary
In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.
Trial Details
NCT Number NCT07514234
Lead Sponsor Gadjah Mada University
Conditions PCOS (Polycystic Ovary Syndrome)
Enrollment 15 participants
Start Date 2023-01-05
Primary Completion 2023-09-11 (estimated)
Study Completion 2025-12-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-07